Trials / Completed
CompletedNCT00140062
Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension.
A Randomized Post-Marketing Efficacy And Safety Study Of Xalatan Compared With "Usual Care" Over 36 Months In Patients With Primary Open-Angle Glaucoma, Exfoliative Glaucoma Or Ocular Hypertension
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 329 (planned)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose is to compare the intraocular pressure reducing effect of Xalatan with that of usual care over 36 months. Safety and health care utilization will be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | latanoprost 0.005% (Xalatan) |
Timeline
- Start date
- 2002-02-01
- Completion
- 2006-04-01
- First posted
- 2005-08-31
- Last updated
- 2008-04-07
Locations
27 sites across 2 countries: Finland, Sweden
Source: ClinicalTrials.gov record NCT00140062. Inclusion in this directory is not an endorsement.